Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1283744

registered interest
date	03/02/2021
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Pensions
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many arrangements the Pensions Regulator has made with pension schemes with a deficit in excess of £50 million since 2005; with which schemes any such arrangements have been made; and for each such scheme, (1) how the deficit was met, and (2) whether there was any difference in the reported deficit and that which had to be met.
tabling member printed	Lord Mendelsohn
uin	HL12969
answer	answer is ministerial correction date of answer 11/02/2021 answer text <p>The information requested on arrangements made by the Pensions Regulator is either not available, or could only be provided at disproportionate cost.</p> answering member printed Baroness Stedman-Scott grouped question UIN HL12970 HL12971 question first answered 11/02/2021 12:22:04 answering member 4174 label Biography information for Baroness Stedman-Scott
tabling member	4286 label Biography information for Lord Mendelsohn

1283745

registered interest
date	03/02/2021
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Pensions
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many arrangements the Pensions Regulator has made with pension schemes with a deficit in excess of £25 million but less than £50 million since 2005; with which schemes any such arrangements have been made; and for each such scheme, (1) how the deficit was met, and (2) whether there was any difference in the reported deficit and that which had to be met.
tabling member printed	Lord Mendelsohn
uin	HL12970
answer	answer is ministerial correction date of answer 11/02/2021 answer text <p>The information requested on arrangements made by the Pensions Regulator is either not available, or could only be provided at disproportionate cost.</p> answering member printed Baroness Stedman-Scott grouped question UIN HL12969 HL12971 question first answered 11/02/2021 12:22:04 answering member 4174 label Biography information for Baroness Stedman-Scott
tabling member	4286 label Biography information for Lord Mendelsohn

1283746

registered interest
date	03/02/2021
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Pensions
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many arrangements the Pensions Regulator has made with pension schemes with a deficit in excess of £10 million but less than £25 million since 2005; with which schemes any such arrangements have been made; and for each such scheme, (1) how the deficit was met, and (2) whether there was any difference in the reported deficit and that which had to be met.
tabling member printed	Lord Mendelsohn
uin	HL12971
answer	answer is ministerial correction date of answer 11/02/2021 answer text <p>The information requested on arrangements made by the Pensions Regulator is either not available, or could only be provided at disproportionate cost.</p> answering member printed Baroness Stedman-Scott grouped question UIN HL12969 HL12970 question first answered 11/02/2021 12:22:04 answering member 4174 label Biography information for Baroness Stedman-Scott
tabling member	4286 label Biography information for Lord Mendelsohn

1278960

registered interest
date	20/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccination: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will list all projects funded by UK Research and Innovation to support research on vaccine responses in groups of immune-supressed individuals; and, in each case, what is (1) the level of funding, and (2) the project timetable.
tabling member printed	Lord Mendelsohn
uin	HL12366
answer	answer is ministerial correction date of answer 03/02/2021 answer text <p>UK Research and Innovation (UKRI) is funding research on vaccine responses in groups of immune-supressed individuals as part of its support for the OCTAVE study in the National Core Studies (NCS) Immunity Programme. The NCS was established in October 2020, guided by an Oversight Committee, chaired by Sir Patrick Vallance (Government Chief Scientific Adviser), to increase research scale and ultimately maintain resilience against Covid-19.</p><p> </p><p>The NCS Oversight Committee members are:</p><ul><li>Professor Sir John Bell (Regius Chair of Medicine, University of Oxford)</li><li>Sir Jeremy Farrar (Director, Wellcome Trust)</li><li>Professor Sir Mike Ferguson (Regius Professor of Life Sciences, University of Dundee)</li><li>Professor Dame Anne Johnson (Professor of Infectious Disease Epidemiology, UCL)</li><li>Sir Harpal Kumar (President, GRAIL Europe)</li><li>Professor Dame Ottoline Leyser (CEO, UKRI)</li><li>Dr Lynda Stuart (Lead COVID-19 Discovery and Translational Vaccine Response Team, Bill &amp; Melinda Gates Foundation)</li><li>Professor Chris Whitty (Chief Medical Officer and Head of the National Institute of Health Research (NIHR))</li></ul><p> </p><p>Plus, representatives of the Devolved Administrations, NIHR and Health and Safety Executive.</p><p> </p><p>Further expert insights are provided by an international panel comprising Peggy Hamburg (Chair of the Board of the American Association for the Advancement of Science), Gagandeep Kang (Professor, Division of Gastrointestinal Sciences, Christian Medical College Vellore) and Gabriel Leung (Dean of Medicine, Hong Kong University).</p><p> </p><p>The OCTAVE study, led by Professor Iain McInnes, University of Glasgow, has a budget of c. £2.3 million, is designed to deliver in twelve months, and is supporting research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. Cancer patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia, and bone marrow transplants. In addition, there are proposals on vaccine responses in high-risk clinical groups under consideration by UKRI’s Medical Research Council (MRC) as part of the UKRI COVID-19 Agile call, including in haematological cancers. These submissions will be reviewed by the MRC’s Agile Panel, which draws on members of the MRC’s Research Boards and Panels, and if supported will be coordinated with the OCTAVE study.</p><p> </p><p>The Government Office for Science, acting as the NCS secretariat, establishes the formal links between the NCS and the policymakers and delivery partners in government (including No 10, Cabinet Office, Department of Health and Social Care, Public Health England and devolved equivalents, and the Joint Biosecurity Centre), ensuring that study outputs support informed policy and operational responses.</p><p> </p> answering member printed Lord Callanan grouped question UIN HL12367 HL12369 HL12371 question first answered 03/02/2021 17:41:32 answering member 4336 label Biography information for Lord Callanan
tabling member	4286 label Biography information for Lord Mendelsohn

1278961

registered interest
date	20/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccination: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government which scientific advisory committees made the evaluations of which projects UK Research and Innovation should fund to support research on vaccine responses in groups of immune-supressed individuals; and who are the members of each such committee.
tabling member printed	Lord Mendelsohn
uin	HL12367
answer	answer is ministerial correction date of answer 03/02/2021 answer text <p>UK Research and Innovation (UKRI) is funding research on vaccine responses in groups of immune-supressed individuals as part of its support for the OCTAVE study in the National Core Studies (NCS) Immunity Programme. The NCS was established in October 2020, guided by an Oversight Committee, chaired by Sir Patrick Vallance (Government Chief Scientific Adviser), to increase research scale and ultimately maintain resilience against Covid-19.</p><p> </p><p>The NCS Oversight Committee members are:</p><ul><li>Professor Sir John Bell (Regius Chair of Medicine, University of Oxford)</li><li>Sir Jeremy Farrar (Director, Wellcome Trust)</li><li>Professor Sir Mike Ferguson (Regius Professor of Life Sciences, University of Dundee)</li><li>Professor Dame Anne Johnson (Professor of Infectious Disease Epidemiology, UCL)</li><li>Sir Harpal Kumar (President, GRAIL Europe)</li><li>Professor Dame Ottoline Leyser (CEO, UKRI)</li><li>Dr Lynda Stuart (Lead COVID-19 Discovery and Translational Vaccine Response Team, Bill &amp; Melinda Gates Foundation)</li><li>Professor Chris Whitty (Chief Medical Officer and Head of the National Institute of Health Research (NIHR))</li></ul><p> </p><p>Plus, representatives of the Devolved Administrations, NIHR and Health and Safety Executive.</p><p> </p><p>Further expert insights are provided by an international panel comprising Peggy Hamburg (Chair of the Board of the American Association for the Advancement of Science), Gagandeep Kang (Professor, Division of Gastrointestinal Sciences, Christian Medical College Vellore) and Gabriel Leung (Dean of Medicine, Hong Kong University).</p><p> </p><p>The OCTAVE study, led by Professor Iain McInnes, University of Glasgow, has a budget of c. £2.3 million, is designed to deliver in twelve months, and is supporting research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. Cancer patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia, and bone marrow transplants. In addition, there are proposals on vaccine responses in high-risk clinical groups under consideration by UKRI’s Medical Research Council (MRC) as part of the UKRI COVID-19 Agile call, including in haematological cancers. These submissions will be reviewed by the MRC’s Agile Panel, which draws on members of the MRC’s Research Boards and Panels, and if supported will be coordinated with the OCTAVE study.</p><p> </p><p>The Government Office for Science, acting as the NCS secretariat, establishes the formal links between the NCS and the policymakers and delivery partners in government (including No 10, Cabinet Office, Department of Health and Social Care, Public Health England and devolved equivalents, and the Joint Biosecurity Centre), ensuring that study outputs support informed policy and operational responses.</p><p> </p> answering member printed Lord Callanan grouped question UIN HL12366 HL12369 HL12371 question first answered 03/02/2021 17:41:32 answering member 4336 label Biography information for Lord Callanan
tabling member	4286 label Biography information for Lord Mendelsohn

1278962

registered interest
date	20/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccination: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they (1) intend to allocate, or (2) would consider allocating on the basis of scientific advice, further funding to UK Research and Innovation to support research on vaccine responses in groups of immune-supressed individuals.
tabling member printed	Lord Mendelsohn
uin	HL12368
answer	answer is ministerial correction date of answer 03/02/2021 answer text <p>The Department’s R&amp;D settlement has increased to £11.1 billion for 2021/22. This includes an ambitious three year settlement for core research funding for National Academies and UK Research and Innovation’s (UKRI) core research budgets. In line with the Haldane Principles, UKRI will determine how funding will be allocated across research councils.</p> answering member printed Lord Callanan question first answered 03/02/2021 17:41:58 answering member 4336 label Biography information for Lord Callanan
tabling member	4286 label Biography information for Lord Mendelsohn

1278963

registered interest
date	20/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccination: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assurances they have received that the research supported by UK Research and Innovation on vaccine responses in groups of immune-supressed individuals is adequate to support advice on responses for all blood cancers; and whether they have consulted Blood Cancer UK on this matter.
tabling member printed	Lord Mendelsohn
uin	HL12369
answer	answer is ministerial correction date of answer 03/02/2021 answer text <p>UK Research and Innovation (UKRI) is funding research on vaccine responses in groups of immune-supressed individuals as part of its support for the OCTAVE study in the National Core Studies (NCS) Immunity Programme. The NCS was established in October 2020, guided by an Oversight Committee, chaired by Sir Patrick Vallance (Government Chief Scientific Adviser), to increase research scale and ultimately maintain resilience against Covid-19.</p><p> </p><p>The NCS Oversight Committee members are:</p><ul><li>Professor Sir John Bell (Regius Chair of Medicine, University of Oxford)</li><li>Sir Jeremy Farrar (Director, Wellcome Trust)</li><li>Professor Sir Mike Ferguson (Regius Professor of Life Sciences, University of Dundee)</li><li>Professor Dame Anne Johnson (Professor of Infectious Disease Epidemiology, UCL)</li><li>Sir Harpal Kumar (President, GRAIL Europe)</li><li>Professor Dame Ottoline Leyser (CEO, UKRI)</li><li>Dr Lynda Stuart (Lead COVID-19 Discovery and Translational Vaccine Response Team, Bill &amp; Melinda Gates Foundation)</li><li>Professor Chris Whitty (Chief Medical Officer and Head of the National Institute of Health Research (NIHR))</li></ul><p> </p><p>Plus, representatives of the Devolved Administrations, NIHR and Health and Safety Executive.</p><p> </p><p>Further expert insights are provided by an international panel comprising Peggy Hamburg (Chair of the Board of the American Association for the Advancement of Science), Gagandeep Kang (Professor, Division of Gastrointestinal Sciences, Christian Medical College Vellore) and Gabriel Leung (Dean of Medicine, Hong Kong University).</p><p> </p><p>The OCTAVE study, led by Professor Iain McInnes, University of Glasgow, has a budget of c. £2.3 million, is designed to deliver in twelve months, and is supporting research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. Cancer patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia, and bone marrow transplants. In addition, there are proposals on vaccine responses in high-risk clinical groups under consideration by UKRI’s Medical Research Council (MRC) as part of the UKRI COVID-19 Agile call, including in haematological cancers. These submissions will be reviewed by the MRC’s Agile Panel, which draws on members of the MRC’s Research Boards and Panels, and if supported will be coordinated with the OCTAVE study.</p><p> </p><p>The Government Office for Science, acting as the NCS secretariat, establishes the formal links between the NCS and the policymakers and delivery partners in government (including No 10, Cabinet Office, Department of Health and Social Care, Public Health England and devolved equivalents, and the Joint Biosecurity Centre), ensuring that study outputs support informed policy and operational responses.</p><p> </p> answering member printed Lord Callanan grouped question UIN HL12366 HL12367 HL12371 question first answered 03/02/2021 17:41:32 answering member 4336 label Biography information for Lord Callanan
tabling member	4286 label Biography information for Lord Mendelsohn

1278964

registered interest
date	20/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment and research they have undertaken in support of advice or guidance for (1) the treatment of, (2) evaluating the risk of, and (3) recommending the most effective vaccine for, Follicular Lymphoma.
tabling member printed	Lord Mendelsohn
uin	HL12370
answer	answer is ministerial correction date of answer 31/03/2021 answer text <p>In 2016, the National Institute for Health and Care Excellence (NICE) published the guideline Non-Hodgkin’s lymphoma: diagnosis and management. The guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years old and over. The guideline includes specific recommendations related to the management and treatment of different stages of follicular lymphoma. A copy of the guideline is attached.</p><p>UK Research and Innovation is funding research on vaccine responses in groups of immune-supressed individual as part of its support for the OCTAVE study in the National Core Studies (NCS) Immunity Programme. The NCS Immunity Programme was established in October 2020 to enable the United Kingdom to use health data and research at scale, recognising the need to respond to near term strategic, policy and operational pressures and ultimately maintain resilience against COVID-19.</p> answering member printed Lord Bethell question first answered 31/03/2021 13:26:04 answering member 4708 label Biography information for Lord Bethell attachment 1 file name nonhodgkins-lymphoma-diagnosis-and-management-pdf-1837509936325.pdf title Non-Hodgkin’s lymphoma: diagnosis and management
tabling member	4286 label Biography information for Lord Mendelsohn

1278993

registered interest
date	20/01/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Vaccination: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government which research projects UK Research and Innovation are funding into vaccine responses for (1) individuals with inflammatory disorders, (2) high risk cancer patient groups, (3) patients with severe kidney and liver disease, and (4) other immune-suppressed individuals.
tabling member printed	Lord Mendelsohn
uin	HL12371
answer	answer is ministerial correction date of answer 03/02/2021 answer text <p>UK Research and Innovation (UKRI) is funding research on vaccine responses in groups of immune-supressed individuals as part of its support for the OCTAVE study in the National Core Studies (NCS) Immunity Programme. The NCS was established in October 2020, guided by an Oversight Committee, chaired by Sir Patrick Vallance (Government Chief Scientific Adviser), to increase research scale and ultimately maintain resilience against Covid-19.</p><p> </p><p>The NCS Oversight Committee members are:</p><ul><li>Professor Sir John Bell (Regius Chair of Medicine, University of Oxford)</li><li>Sir Jeremy Farrar (Director, Wellcome Trust)</li><li>Professor Sir Mike Ferguson (Regius Professor of Life Sciences, University of Dundee)</li><li>Professor Dame Anne Johnson (Professor of Infectious Disease Epidemiology, UCL)</li><li>Sir Harpal Kumar (President, GRAIL Europe)</li><li>Professor Dame Ottoline Leyser (CEO, UKRI)</li><li>Dr Lynda Stuart (Lead COVID-19 Discovery and Translational Vaccine Response Team, Bill &amp; Melinda Gates Foundation)</li><li>Professor Chris Whitty (Chief Medical Officer and Head of the National Institute of Health Research (NIHR))</li></ul><p> </p><p>Plus, representatives of the Devolved Administrations, NIHR and Health and Safety Executive.</p><p> </p><p>Further expert insights are provided by an international panel comprising Peggy Hamburg (Chair of the Board of the American Association for the Advancement of Science), Gagandeep Kang (Professor, Division of Gastrointestinal Sciences, Christian Medical College Vellore) and Gabriel Leung (Dean of Medicine, Hong Kong University).</p><p> </p><p>The OCTAVE study, led by Professor Iain McInnes, University of Glasgow, has a budget of c. £2.3 million, is designed to deliver in twelve months, and is supporting research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. Cancer patient groups include chronic lymphocytic leukaemia, myeloma, acute leukaemia, and bone marrow transplants. In addition, there are proposals on vaccine responses in high-risk clinical groups under consideration by UKRI’s Medical Research Council (MRC) as part of the UKRI COVID-19 Agile call, including in haematological cancers. These submissions will be reviewed by the MRC’s Agile Panel, which draws on members of the MRC’s Research Boards and Panels, and if supported will be coordinated with the OCTAVE study.</p><p> </p><p>The Government Office for Science, acting as the NCS secretariat, establishes the formal links between the NCS and the policymakers and delivery partners in government (including No 10, Cabinet Office, Department of Health and Social Care, Public Health England and devolved equivalents, and the Joint Biosecurity Centre), ensuring that study outputs support informed policy and operational responses.</p><p> </p> answering member printed Lord Callanan grouped question UIN HL12366 HL12367 HL12369 question first answered 03/02/2021 17:41:32 answering member 4336 label Biography information for Lord Callanan
tabling member	4286 label Biography information for Lord Mendelsohn

1274595

registered interest
date	07/01/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what funding they are providing for research into COVID-19 vaccines for medically extremely vulnerable groups.
tabling member printed	Lord Mendelsohn
uin	HL11893
answer	answer is ministerial correction date of answer 19/01/2021 answer text <p>The Department commissions research through the National Institute for Health Research which is funding a wide portfolio of research on COVID-19 vaccination, including allocating over £50 million specifically to develop COVID-19 vaccines at the University of Oxford and Imperial College London.</p><p>In addition, UK Research and Innovation is providing around £2 million to support research on vaccine responses in groups of immune-supressed individuals, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease.</p> answering member printed Lord Bethell question first answered 19/01/2021 12:39:22 answering member 4708 label Biography information for Lord Bethell
tabling member	4286 label Biography information for Lord Mendelsohn